Tempus AI Inc. , considered one of the top AI stocks among hedge funds, has achieved a major milestone through its subsidiary, Ambry Genetics. On June 25, Ambry Genetics announced the publication of a peer-reviewed study in the Journal of the National Comprehensive Cancer Network (JNCCN), validating the accuracy of its digital hereditary cancer risk assessment tool—the Ambry CARE Program.
The study, titled "Validation of a Digital Tool that Uses National Testing Guidelines to Identify Individuals at Risk for Hereditary Cancer," found that the CARE program applies the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology with a 99.5% accuracy rate. This high level of precision confirms CARE's effectiveness in helping healthcare providers identify individuals who may benefit from hereditary cancer genetic testing and tailored interventions.
Hereditary cancer risk is often underdiagnosed—approximately 5% of people carry mutations in cancer predisposition genes but remain unaware. While NCCN Guidelines provide a comprehensive framework for testing, their complexity and regular updates can be difficult for non-specialist clinicians and existing digital tools to navigate. CARE addresses this gap by offering an efficient, accurate, and easy-to-use solution for hereditary cancer risk evaluation.
Tempus AI is a leading healthcare technology company leveraging artificial intelligence to personalize and optimize patient care. Ambry Genetics, a wholly owned subsidiary of Tempus AI, focuses on translating cutting-edge genomic research into clinically relevant insights, enabling healthcare providers to make more informed decisions for patients with genetic conditions.
This validation study further solidifies Tempus AI’s role in advancing precision medicine, particularly in cancer care, through the integration of AI and genomic science.